nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLC47A1—Mitoxantrone—sarcoma	0.275	0.508	CbGbCtD
Sirolimus—CYP3A7—Vincristine—sarcoma	0.0319	0.059	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0319	0.059	CbGbCtD
Sirolimus—CYP3A4—Thiotepa—sarcoma	0.0315	0.0583	CbGbCtD
Sirolimus—ABCB1—Dactinomycin—sarcoma	0.0253	0.0468	CbGbCtD
Sirolimus—CYP3A5—Vincristine—sarcoma	0.0239	0.0442	CbGbCtD
Sirolimus—ABCB1—Mitoxantrone—sarcoma	0.0226	0.0418	CbGbCtD
Sirolimus—CYP3A5—Etoposide—sarcoma	0.0219	0.0405	CbGbCtD
Sirolimus—ABCB1—Vincristine—sarcoma	0.0156	0.0288	CbGbCtD
Sirolimus—ABCB1—Etoposide—sarcoma	0.0143	0.0264	CbGbCtD
Sirolimus—CYP3A4—Mitoxantrone—sarcoma	0.0135	0.0251	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—sarcoma	0.00972	0.018	CbGbCtD
Sirolimus—CYP3A4—Vincristine—sarcoma	0.00932	0.0173	CbGbCtD
Sirolimus—CYP3A4—Etoposide—sarcoma	0.00854	0.0158	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—sarcoma	0.00583	0.0108	CbGbCtD
Sirolimus—MTOR—leg—sarcoma	0.00551	0.0586	CbGeAlD
Sirolimus—MTOR—forelimb—sarcoma	0.00547	0.0581	CbGeAlD
Sirolimus—MTOR—hindlimb—sarcoma	0.00492	0.0523	CbGeAlD
Sirolimus—MTOR—appendage—sarcoma	0.00422	0.0449	CbGeAlD
Sirolimus—EIF4E—embryo—sarcoma	0.00362	0.0385	CbGeAlD
Sirolimus—FGF2—mammary gland—sarcoma	0.00324	0.0344	CbGeAlD
Sirolimus—EIF4E—hematopoietic system—sarcoma	0.00323	0.0344	CbGeAlD
Sirolimus—EIF4E—connective tissue—sarcoma	0.00311	0.0331	CbGeAlD
Sirolimus—EIF4E—uterus—sarcoma	0.00244	0.026	CbGeAlD
Sirolimus—FGF2—myometrium—sarcoma	0.0023	0.0244	CbGeAlD
Sirolimus—EIF4E—lymphoid tissue—sarcoma	0.00228	0.0242	CbGeAlD
Sirolimus—MTOR—mammary gland—sarcoma	0.00205	0.0218	CbGeAlD
Sirolimus—FKBP1A—mammary gland—sarcoma	0.00185	0.0196	CbGeAlD
Sirolimus—EIF4E—testis—sarcoma	0.00177	0.0188	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—sarcoma	0.00174	0.0185	CbGeAlD
Sirolimus—EIF4E—liver—sarcoma	0.00167	0.0178	CbGeAlD
Sirolimus—SLCO1B1—mammary gland—sarcoma	0.00157	0.0167	CbGeAlD
Sirolimus—FGF2—uterus—sarcoma	0.00149	0.0158	CbGeAlD
Sirolimus—MTOR—myometrium—sarcoma	0.00146	0.0155	CbGeAlD
Sirolimus—MTOR—embryo—sarcoma	0.0014	0.0149	CbGeAlD
Sirolimus—MTOR—seminal vesicle—sarcoma	0.00132	0.014	CbGeAlD
Sirolimus—FKBP1A—myometrium—sarcoma	0.00131	0.0139	CbGeAlD
Sirolimus—FGF2—tendon—sarcoma	0.0013	0.0139	CbGeAlD
Sirolimus—MTOR—hematopoietic system—sarcoma	0.00125	0.0133	CbGeAlD
Sirolimus—MTOR—connective tissue—sarcoma	0.0012	0.0128	CbGeAlD
Sirolimus—FKBP1A—seminal vesicle—sarcoma	0.00118	0.0126	CbGeAlD
Sirolimus—SLC47A1—myometrium—sarcoma	0.00113	0.012	CbGeAlD
Sirolimus—FKBP1A—hematopoietic system—sarcoma	0.00112	0.012	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—sarcoma	0.0011	0.0117	CbGeAlD
Sirolimus—MTOR—skin of body—sarcoma	0.00109	0.0116	CbGeAlD
Sirolimus—FKBP1A—connective tissue—sarcoma	0.00108	0.0115	CbGeAlD
Sirolimus—FGF2—testis—sarcoma	0.00108	0.0115	CbGeAlD
Sirolimus—SLC47A1—seminal vesicle—sarcoma	0.00102	0.0108	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—sarcoma	0.000991	0.0105	CbGeAlD
Sirolimus—FKBP1A—skin of body—sarcoma	0.000978	0.0104	CbGeAlD
Sirolimus—SLC47A1—hematopoietic system—sarcoma	0.000967	0.0103	CbGeAlD
Sirolimus—SLCO1B1—hematopoietic system—sarcoma	0.000954	0.0101	CbGeAlD
Sirolimus—MTOR—uterus—sarcoma	0.000945	0.01	CbGeAlD
Sirolimus—MTOR—lymphoid tissue—sarcoma	0.00088	0.00936	CbGeAlD
Sirolimus—FKBP1A—cardiac atrium—sarcoma	0.000854	0.00908	CbGeAlD
Sirolimus—FKBP1A—uterus—sarcoma	0.00085	0.00903	CbGeAlD
Sirolimus—MTOR—tendon—sarcoma	0.000828	0.0088	CbGeAlD
Sirolimus—MTOR—bone marrow—sarcoma	0.000802	0.00852	CbGeAlD
Sirolimus—FKBP1A—lymphoid tissue—sarcoma	0.000792	0.00842	CbGeAlD
Sirolimus—FGF2—lymph node—sarcoma	0.000783	0.00833	CbGeAlD
Sirolimus—FKBP1A—tendon—sarcoma	0.000744	0.00792	CbGeAlD
Sirolimus—SLC47A1—uterus—sarcoma	0.00073	0.00776	CbGeAlD
Sirolimus—FKBP1A—bone marrow—sarcoma	0.000721	0.00767	CbGeAlD
Sirolimus—CYP3A7—liver—sarcoma	0.000721	0.00767	CbGeAlD
Sirolimus—MTOR—testis—sarcoma	0.000685	0.00729	CbGeAlD
Sirolimus—MTOR—liver—sarcoma	0.000648	0.00689	CbGeAlD
Sirolimus—SLC47A1—tendon—sarcoma	0.00064	0.0068	CbGeAlD
Sirolimus—FKBP1A—testis—sarcoma	0.000616	0.00655	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—liver—sarcoma	0.000613	0.00652	CbGeAlD
Sirolimus—FKBP1A—liver—sarcoma	0.000583	0.0062	CbGeAlD
Sirolimus—SLC47A1—testis—sarcoma	0.00053	0.00563	CbGeAlD
Sirolimus—SLC47A1—liver—sarcoma	0.000501	0.00533	CbGeAlD
Sirolimus—MTOR—lymph node—sarcoma	0.000497	0.00528	CbGeAlD
Sirolimus—SLCO1B1—liver—sarcoma	0.000494	0.00526	CbGeAlD
Sirolimus—CYP3A5—hematopoietic system—sarcoma	0.00049	0.00521	CbGeAlD
Sirolimus—FKBP1A—lymph node—sarcoma	0.000447	0.00475	CbGeAlD
Sirolimus—SLC47A1—lymph node—sarcoma	0.000384	0.00408	CbGeAlD
Sirolimus—CYP3A4—hematopoietic system—sarcoma	0.000368	0.00391	CbGeAlD
Sirolimus—ABCB1—myometrium—sarcoma	0.000303	0.00322	CbGeAlD
Sirolimus—ABCB1—embryo—sarcoma	0.000291	0.0031	CbGeAlD
Sirolimus—ABCB1—seminal vesicle—sarcoma	0.000274	0.00291	CbGeAlD
Sirolimus—ABCB1—hematopoietic system—sarcoma	0.00026	0.00277	CbGeAlD
Sirolimus—CYP3A5—liver—sarcoma	0.000254	0.0027	CbGeAlD
Sirolimus—ABCB1—uterus—sarcoma	0.000197	0.00209	CbGeAlD
Sirolimus—CYP3A4—liver—sarcoma	0.00019	0.00202	CbGeAlD
Sirolimus—ABCB1—lymphoid tissue—sarcoma	0.000183	0.00195	CbGeAlD
Sirolimus—ABCB1—bone marrow—sarcoma	0.000167	0.00177	CbGeAlD
Sirolimus—ABCB1—testis—sarcoma	0.000143	0.00152	CbGeAlD
Sirolimus—ABCB1—liver—sarcoma	0.000135	0.00143	CbGeAlD
Sirolimus—Diarrhoea—Thiotepa—sarcoma	0.00013	0.000634	CcSEcCtD
Sirolimus—Abdominal pain—Mitoxantrone—sarcoma	0.000129	0.000633	CcSEcCtD
Sirolimus—Body temperature increased—Mitoxantrone—sarcoma	0.000129	0.000633	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000129	0.000633	CcSEcCtD
Sirolimus—Bronchitis—Epirubicin—sarcoma	0.000129	0.000631	CcSEcCtD
Sirolimus—Diarrhoea—Dactinomycin—sarcoma	0.000129	0.00063	CcSEcCtD
Sirolimus—Pancytopenia—Epirubicin—sarcoma	0.000127	0.000623	CcSEcCtD
Sirolimus—Hypotension—Etoposide—sarcoma	0.000127	0.000622	CcSEcCtD
Sirolimus—Gastritis—Doxorubicin—sarcoma	0.000127	0.000622	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000127	0.00062	CcSEcCtD
Sirolimus—Dysuria—Epirubicin—sarcoma	0.000125	0.000614	CcSEcCtD
Sirolimus—Neutropenia—Epirubicin—sarcoma	0.000125	0.000614	CcSEcCtD
Sirolimus—Dizziness—Thiotepa—sarcoma	0.000125	0.000613	CcSEcCtD
Sirolimus—Abdominal distension—Doxorubicin—sarcoma	0.000125	0.000611	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Epirubicin—sarcoma	0.000125	0.00061	CcSEcCtD
Sirolimus—Influenza—Doxorubicin—sarcoma	0.000124	0.000607	CcSEcCtD
Sirolimus—Asthma—Doxorubicin—sarcoma	0.000124	0.000607	CcSEcCtD
Sirolimus—Dysphagia—Doxorubicin—sarcoma	0.000124	0.000607	CcSEcCtD
Sirolimus—Pollakiuria—Epirubicin—sarcoma	0.000124	0.000606	CcSEcCtD
Sirolimus—Hypersensitivity—Vincristine—sarcoma	0.000124	0.000606	CcSEcCtD
Sirolimus—Paraesthesia—Etoposide—sarcoma	0.000122	0.000598	CcSEcCtD
Sirolimus—Weight increased—Epirubicin—sarcoma	0.000122	0.000597	CcSEcCtD
Sirolimus—Pancreatitis—Doxorubicin—sarcoma	0.000122	0.000595	CcSEcCtD
Sirolimus—Weight decreased—Epirubicin—sarcoma	0.000121	0.000594	CcSEcCtD
Sirolimus—Dyspnoea—Etoposide—sarcoma	0.000121	0.000594	CcSEcCtD
Sirolimus—Hyperglycaemia—Epirubicin—sarcoma	0.000121	0.000592	CcSEcCtD
Sirolimus—Somnolence—Etoposide—sarcoma	0.000121	0.000592	CcSEcCtD
Sirolimus—Hypersensitivity—Mitoxantrone—sarcoma	0.00012	0.00059	CcSEcCtD
Sirolimus—Asthenia—Vincristine—sarcoma	0.00012	0.00059	CcSEcCtD
Sirolimus—Vomiting—Thiotepa—sarcoma	0.00012	0.000589	CcSEcCtD
Sirolimus—Pneumonia—Epirubicin—sarcoma	0.00012	0.000589	CcSEcCtD
Sirolimus—Infestation NOS—Epirubicin—sarcoma	0.000119	0.000585	CcSEcCtD
Sirolimus—Infestation—Epirubicin—sarcoma	0.000119	0.000585	CcSEcCtD
Sirolimus—Vomiting—Dactinomycin—sarcoma	0.000119	0.000585	CcSEcCtD
Sirolimus—Rash—Thiotepa—sarcoma	0.000119	0.000585	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—sarcoma	0.000119	0.000584	CcSEcCtD
Sirolimus—Dermatitis—Thiotepa—sarcoma	0.000119	0.000584	CcSEcCtD
Sirolimus—Headache—Thiotepa—sarcoma	0.000119	0.000581	CcSEcCtD
Sirolimus—Rash—Dactinomycin—sarcoma	0.000118	0.00058	CcSEcCtD
Sirolimus—Decreased appetite—Etoposide—sarcoma	0.000118	0.000579	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—sarcoma	0.000118	0.000577	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Etoposide—sarcoma	0.000117	0.000575	CcSEcCtD
Sirolimus—Asthenia—Mitoxantrone—sarcoma	0.000117	0.000574	CcSEcCtD
Sirolimus—Neuropathy peripheral—Epirubicin—sarcoma	0.000117	0.000574	CcSEcCtD
Sirolimus—Stomatitis—Epirubicin—sarcoma	0.000116	0.000571	CcSEcCtD
Sirolimus—Pain—Etoposide—sarcoma	0.000116	0.000569	CcSEcCtD
Sirolimus—Constipation—Etoposide—sarcoma	0.000116	0.000569	CcSEcCtD
Sirolimus—Conjunctivitis—Epirubicin—sarcoma	0.000116	0.000569	CcSEcCtD
Sirolimus—Urinary tract infection—Epirubicin—sarcoma	0.000116	0.000569	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—sarcoma	0.000116	0.000568	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—sarcoma	0.000116	0.000568	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000115	0.000564	CcSEcCtD
Sirolimus—Diarrhoea—Vincristine—sarcoma	0.000115	0.000562	CcSEcCtD
Sirolimus—Sweating—Epirubicin—sarcoma	0.000115	0.000561	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—sarcoma	0.000115	0.000561	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—sarcoma	0.000114	0.000558	CcSEcCtD
Sirolimus—Hepatobiliary disease—Epirubicin—sarcoma	0.000113	0.000554	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—sarcoma	0.000113	0.000553	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—sarcoma	0.000113	0.000552	CcSEcCtD
Sirolimus—Nausea—Thiotepa—sarcoma	0.000112	0.000551	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—sarcoma	0.000112	0.00055	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—sarcoma	0.000112	0.000549	CcSEcCtD
Sirolimus—Feeling abnormal—Etoposide—sarcoma	0.000112	0.000549	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—sarcoma	0.000112	0.000548	CcSEcCtD
Sirolimus—Diarrhoea—Mitoxantrone—sarcoma	0.000112	0.000548	CcSEcCtD
Sirolimus—Nausea—Dactinomycin—sarcoma	0.000112	0.000547	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—sarcoma	0.000111	0.000545	CcSEcCtD
Sirolimus—Gastrointestinal pain—Etoposide—sarcoma	0.000111	0.000545	CcSEcCtD
Sirolimus—Dizziness—Vincristine—sarcoma	0.000111	0.000544	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—sarcoma	0.000111	0.000542	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—sarcoma	0.000111	0.000542	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—sarcoma	0.000108	0.000531	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—sarcoma	0.000108	0.000528	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—sarcoma	0.000108	0.000528	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—sarcoma	0.000108	0.000527	CcSEcCtD
Sirolimus—Abdominal pain—Etoposide—sarcoma	0.000107	0.000526	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—sarcoma	0.000107	0.000526	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—sarcoma	0.000107	0.000526	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—sarcoma	0.000107	0.000526	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—sarcoma	0.000107	0.000525	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—sarcoma	0.000107	0.000523	CcSEcCtD
Sirolimus—Vomiting—Vincristine—sarcoma	0.000107	0.000523	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—sarcoma	0.000106	0.000521	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—sarcoma	0.000106	0.000519	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—sarcoma	0.000106	0.000519	CcSEcCtD
Sirolimus—Rash—Vincristine—sarcoma	0.000106	0.000518	CcSEcCtD
Sirolimus—Dermatitis—Vincristine—sarcoma	0.000106	0.000518	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—sarcoma	0.000106	0.000518	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—sarcoma	0.000105	0.000516	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—sarcoma	0.000105	0.000516	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—sarcoma	0.000105	0.000515	CcSEcCtD
Sirolimus—Headache—Vincristine—sarcoma	0.000105	0.000515	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—sarcoma	0.000105	0.000512	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—sarcoma	0.000104	0.000511	CcSEcCtD
Sirolimus—Vomiting—Mitoxantrone—sarcoma	0.000104	0.000509	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—sarcoma	0.000104	0.000508	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—sarcoma	0.000103	0.000506	CcSEcCtD
Sirolimus—ABCB1—lymph node—sarcoma	0.000103	0.0011	CbGeAlD
Sirolimus—Rash—Mitoxantrone—sarcoma	0.000103	0.000505	CcSEcCtD
Sirolimus—Dermatitis—Mitoxantrone—sarcoma	0.000103	0.000504	CcSEcCtD
Sirolimus—Headache—Mitoxantrone—sarcoma	0.000102	0.000502	CcSEcCtD
Sirolimus—Hypersensitivity—Etoposide—sarcoma	0.0001	0.000491	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—sarcoma	0.0001	0.00049	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—sarcoma	9.98e-05	0.000489	CcSEcCtD
Sirolimus—Nausea—Vincristine—sarcoma	9.97e-05	0.000488	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—sarcoma	9.96e-05	0.000488	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—sarcoma	9.95e-05	0.000487	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—sarcoma	9.93e-05	0.000486	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—sarcoma	9.88e-05	0.000484	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—sarcoma	9.85e-05	0.000483	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—sarcoma	9.8e-05	0.00048	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—sarcoma	9.78e-05	0.000479	CcSEcCtD
Sirolimus—Asthenia—Etoposide—sarcoma	9.76e-05	0.000478	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—sarcoma	9.75e-05	0.000478	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—sarcoma	9.73e-05	0.000477	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—sarcoma	9.73e-05	0.000477	CcSEcCtD
Sirolimus—Nausea—Mitoxantrone—sarcoma	9.71e-05	0.000476	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—sarcoma	9.69e-05	0.000475	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—sarcoma	9.67e-05	0.000474	CcSEcCtD
Sirolimus—Chills—Epirubicin—sarcoma	9.63e-05	0.000471	CcSEcCtD
Sirolimus—Pruritus—Etoposide—sarcoma	9.62e-05	0.000471	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—sarcoma	9.57e-05	0.000469	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—sarcoma	9.34e-05	0.000457	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—sarcoma	9.3e-05	0.000456	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—sarcoma	9.25e-05	0.000453	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—sarcoma	9.21e-05	0.000451	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—sarcoma	9.2e-05	0.000451	CcSEcCtD
Sirolimus—Tension—Epirubicin—sarcoma	9.16e-05	0.000449	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—sarcoma	9.07e-05	0.000444	CcSEcCtD
Sirolimus—Back pain—Epirubicin—sarcoma	9.03e-05	0.000442	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—sarcoma	9.01e-05	0.000441	CcSEcCtD
Sirolimus—Dizziness—Etoposide—sarcoma	8.99e-05	0.00044	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—sarcoma	8.98e-05	0.00044	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—sarcoma	8.97e-05	0.000439	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—sarcoma	8.95e-05	0.000438	CcSEcCtD
Sirolimus—Chills—Doxorubicin—sarcoma	8.91e-05	0.000436	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—sarcoma	8.66e-05	0.000424	CcSEcCtD
Sirolimus—Vomiting—Etoposide—sarcoma	8.64e-05	0.000423	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—sarcoma	8.64e-05	0.000423	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—sarcoma	8.63e-05	0.000423	CcSEcCtD
Sirolimus—Agitation—Epirubicin—sarcoma	8.58e-05	0.00042	CcSEcCtD
Sirolimus—Rash—Etoposide—sarcoma	8.57e-05	0.00042	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—sarcoma	8.56e-05	0.000419	CcSEcCtD
Sirolimus—Headache—Etoposide—sarcoma	8.52e-05	0.000417	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—sarcoma	8.51e-05	0.000417	CcSEcCtD
Sirolimus—Tension—Doxorubicin—sarcoma	8.48e-05	0.000415	CcSEcCtD
Sirolimus—Malaise—Epirubicin—sarcoma	8.42e-05	0.000412	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—sarcoma	8.39e-05	0.000411	CcSEcCtD
Sirolimus—Syncope—Epirubicin—sarcoma	8.37e-05	0.00041	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—sarcoma	8.36e-05	0.000409	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—sarcoma	8.36e-05	0.000409	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—sarcoma	8.31e-05	0.000407	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—sarcoma	8.25e-05	0.000404	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—sarcoma	8.21e-05	0.000402	CcSEcCtD
Sirolimus—Cough—Epirubicin—sarcoma	8.15e-05	0.000399	CcSEcCtD
Sirolimus—Nausea—Etoposide—sarcoma	8.08e-05	0.000396	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—sarcoma	8.06e-05	0.000395	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—sarcoma	8.02e-05	0.000393	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—sarcoma	7.99e-05	0.000391	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—sarcoma	7.95e-05	0.000389	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—sarcoma	7.95e-05	0.000389	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—sarcoma	7.95e-05	0.000389	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—sarcoma	7.94e-05	0.000389	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—sarcoma	7.92e-05	0.000388	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	7.9e-05	0.000387	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—sarcoma	7.86e-05	0.000385	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—sarcoma	7.79e-05	0.000382	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—sarcoma	7.75e-05	0.00038	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—sarcoma	7.73e-05	0.000379	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—sarcoma	7.68e-05	0.000376	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—sarcoma	7.64e-05	0.000374	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—sarcoma	7.62e-05	0.000373	CcSEcCtD
Sirolimus—Oedema—Epirubicin—sarcoma	7.62e-05	0.000373	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—sarcoma	7.59e-05	0.000372	CcSEcCtD
Sirolimus—Infection—Epirubicin—sarcoma	7.57e-05	0.000371	CcSEcCtD
Sirolimus—Cough—Doxorubicin—sarcoma	7.54e-05	0.000369	CcSEcCtD
Sirolimus—Shock—Epirubicin—sarcoma	7.5e-05	0.000367	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—sarcoma	7.47e-05	0.000366	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—sarcoma	7.46e-05	0.000365	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—sarcoma	7.46e-05	0.000365	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—sarcoma	7.44e-05	0.000364	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—sarcoma	7.4e-05	0.000363	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—sarcoma	7.37e-05	0.000361	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—sarcoma	7.36e-05	0.00036	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—sarcoma	7.36e-05	0.00036	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—sarcoma	7.36e-05	0.00036	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—sarcoma	7.33e-05	0.000359	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	7.31e-05	0.000358	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—sarcoma	7.27e-05	0.000356	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—sarcoma	7.26e-05	0.000356	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—sarcoma	7.12e-05	0.000349	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—sarcoma	7.11e-05	0.000348	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—sarcoma	7.05e-05	0.000345	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—sarcoma	7.05e-05	0.000345	CcSEcCtD
Sirolimus—Infection—Doxorubicin—sarcoma	7.01e-05	0.000343	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—sarcoma	6.94e-05	0.00034	CcSEcCtD
Sirolimus—Shock—Doxorubicin—sarcoma	6.94e-05	0.00034	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—sarcoma	6.92e-05	0.000339	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—sarcoma	6.9e-05	0.000338	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—sarcoma	6.89e-05	0.000338	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—sarcoma	6.88e-05	0.000337	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—sarcoma	6.85e-05	0.000335	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—sarcoma	6.84e-05	0.000335	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—sarcoma	6.82e-05	0.000334	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—sarcoma	6.79e-05	0.000333	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—sarcoma	6.78e-05	0.000332	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—sarcoma	6.72e-05	0.000329	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—sarcoma	6.71e-05	0.000329	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—sarcoma	6.63e-05	0.000324	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—sarcoma	6.59e-05	0.000323	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—sarcoma	6.58e-05	0.000322	CcSEcCtD
Sirolimus—Pain—Epirubicin—sarcoma	6.52e-05	0.000319	CcSEcCtD
Sirolimus—Constipation—Epirubicin—sarcoma	6.52e-05	0.000319	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—sarcoma	6.42e-05	0.000315	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—sarcoma	6.38e-05	0.000312	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—sarcoma	6.33e-05	0.00031	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—sarcoma	6.29e-05	0.000308	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—sarcoma	6.28e-05	0.000308	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—sarcoma	6.27e-05	0.000307	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—sarcoma	6.23e-05	0.000305	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—sarcoma	6.21e-05	0.000304	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—sarcoma	6.13e-05	0.0003	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—sarcoma	6.09e-05	0.000298	CcSEcCtD
Sirolimus—Pain—Doxorubicin—sarcoma	6.03e-05	0.000295	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—sarcoma	6.03e-05	0.000295	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—sarcoma	6.02e-05	0.000295	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—sarcoma	6.02e-05	0.000295	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—sarcoma	5.81e-05	0.000285	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—sarcoma	5.77e-05	0.000282	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—sarcoma	5.62e-05	0.000275	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—sarcoma	5.57e-05	0.000273	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—sarcoma	5.57e-05	0.000273	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—sarcoma	5.47e-05	0.000268	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—sarcoma	5.39e-05	0.000264	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—sarcoma	5.21e-05	0.000255	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—sarcoma	5.2e-05	0.000254	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—sarcoma	5.06e-05	0.000248	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—sarcoma	5.04e-05	0.000247	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—sarcoma	4.99e-05	0.000244	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—sarcoma	4.85e-05	0.000237	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—sarcoma	4.83e-05	0.000236	CcSEcCtD
Sirolimus—Rash—Epirubicin—sarcoma	4.81e-05	0.000235	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—sarcoma	4.8e-05	0.000235	CcSEcCtD
Sirolimus—Headache—Epirubicin—sarcoma	4.77e-05	0.000234	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—sarcoma	4.66e-05	0.000228	CcSEcCtD
Sirolimus—Nausea—Epirubicin—sarcoma	4.53e-05	0.000222	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—sarcoma	4.48e-05	0.00022	CcSEcCtD
Sirolimus—Rash—Doxorubicin—sarcoma	4.45e-05	0.000218	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—sarcoma	4.44e-05	0.000218	CcSEcCtD
Sirolimus—Headache—Doxorubicin—sarcoma	4.42e-05	0.000216	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—ATF1—sarcoma	4.26e-05	0.000264	CbGpPWpGaD
Sirolimus—MTOR—Disease—ENO2—sarcoma	4.25e-05	0.000263	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	4.22e-05	0.000261	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	4.2e-05	0.00026	CbGpPWpGaD
Sirolimus—Nausea—Doxorubicin—sarcoma	4.19e-05	0.000205	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—VEGFA—sarcoma	4.05e-05	0.000251	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	4.03e-05	0.000249	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—sarcoma	4.03e-05	0.000249	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—sarcoma	4.03e-05	0.000249	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MDM2—sarcoma	4.03e-05	0.000249	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—sarcoma	3.99e-05	0.000247	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTPRC—sarcoma	3.99e-05	0.000247	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—sarcoma	3.96e-05	0.000245	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—sarcoma	3.94e-05	0.000244	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PLCG1—sarcoma	3.9e-05	0.000242	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—SRC—sarcoma	3.9e-05	0.000241	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MDM2—sarcoma	3.84e-05	0.000238	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TLE1—sarcoma	3.81e-05	0.000236	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CTNNB1—sarcoma	3.76e-05	0.000232	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—NRAS—sarcoma	3.75e-05	0.000232	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FOXO1—sarcoma	3.73e-05	0.000231	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—sarcoma	3.73e-05	0.000231	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PDGFRB—sarcoma	3.72e-05	0.000231	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ATF1—sarcoma	3.71e-05	0.00023	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—sarcoma	3.7e-05	0.000229	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—MDM2—sarcoma	3.69e-05	0.000229	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PDGFRA—sarcoma	3.67e-05	0.000227	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KIT—sarcoma	3.62e-05	0.000224	CbGpPWpGaD
Sirolimus—MTOR—Disease—PLCG1—sarcoma	3.6e-05	0.000223	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL2—sarcoma	3.6e-05	0.000223	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.6e-05	0.000223	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KDR—sarcoma	3.59e-05	0.000222	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	3.57e-05	0.000221	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—JUN—sarcoma	3.5e-05	0.000217	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KIT—sarcoma	3.48e-05	0.000215	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CTNNB1—sarcoma	3.47e-05	0.000215	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KIT—sarcoma	3.46e-05	0.000214	CbGpPWpGaD
Sirolimus—MTOR—Disease—CXCR4—sarcoma	3.46e-05	0.000214	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FLT1—sarcoma	3.46e-05	0.000214	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CREB1—sarcoma	3.45e-05	0.000213	CbGpPWpGaD
Sirolimus—FGF2—Disease—FOXO1—sarcoma	3.45e-05	0.000213	CbGpPWpGaD
Sirolimus—FGF2—Disease—PDGFRB—sarcoma	3.44e-05	0.000213	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—sarcoma	3.42e-05	0.000212	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PLCG1—sarcoma	3.4e-05	0.00021	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—SRC—sarcoma	3.39e-05	0.00021	CbGpPWpGaD
Sirolimus—FGF2—Disease—PDGFRA—sarcoma	3.39e-05	0.00021	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1R—sarcoma	3.34e-05	0.000207	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—JUN—sarcoma	3.34e-05	0.000207	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CTNNB1—sarcoma	3.32e-05	0.000205	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CREB1—sarcoma	3.31e-05	0.000205	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KIT—sarcoma	3.31e-05	0.000205	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—VEGFA—sarcoma	3.31e-05	0.000205	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CREB1—sarcoma	3.3e-05	0.000204	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCR4—sarcoma	3.27e-05	0.000202	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NRAS—sarcoma	3.27e-05	0.000202	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ATF1—sarcoma	3.23e-05	0.0002	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KRAS—sarcoma	3.23e-05	0.0002	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFC—sarcoma	3.21e-05	0.000199	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FOXO1—sarcoma	3.18e-05	0.000197	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PDGFRB—sarcoma	3.18e-05	0.000197	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CREB1—sarcoma	3.15e-05	0.000195	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—SRC—sarcoma	3.14e-05	0.000194	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PDGFRA—sarcoma	3.13e-05	0.000194	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—sarcoma	3.06e-05	0.000189	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO2—sarcoma	3.06e-05	0.000189	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—HBA1—sarcoma	3.04e-05	0.000188	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NRAS—sarcoma	3.02e-05	0.000187	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—SRC—sarcoma	3e-05	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—sarcoma	2.97e-05	0.000184	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.97e-05	0.000184	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—sarcoma	2.88e-05	0.000179	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—SRC—sarcoma	2.88e-05	0.000178	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MDM2—sarcoma	2.85e-05	0.000177	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KIT—sarcoma	2.84e-05	0.000176	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—KRAS—sarcoma	2.81e-05	0.000174	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO2—sarcoma	2.81e-05	0.000174	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—sarcoma	2.8e-05	0.000173	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—HBA1—sarcoma	2.79e-05	0.000173	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FOXO1—sarcoma	2.77e-05	0.000171	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—NRAS—sarcoma	2.77e-05	0.000171	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PDGFRB—sarcoma	2.76e-05	0.000171	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—sarcoma	2.75e-05	0.00017	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—sarcoma	2.74e-05	0.00017	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—MDM2—sarcoma	2.74e-05	0.00017	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MDM2—sarcoma	2.73e-05	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PDGFRA—sarcoma	2.72e-05	0.000168	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CREB1—sarcoma	2.71e-05	0.000168	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KDR—sarcoma	2.63e-05	0.000163	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—sarcoma	2.63e-05	0.000163	CbGpPWpGaD
Sirolimus—FGF2—Disease—KIT—sarcoma	2.63e-05	0.000162	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MDM2—sarcoma	2.6e-05	0.000161	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KRAS—sarcoma	2.6e-05	0.000161	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PLCG1—sarcoma	2.6e-05	0.000161	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.59e-05	0.00016	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.59e-05	0.00016	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FLT1—sarcoma	2.57e-05	0.000159	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.57e-05	0.000159	CbGpPWpGaD
Sirolimus—MTOR—Disease—FOXO1—sarcoma	2.56e-05	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Disease—PDGFRB—sarcoma	2.55e-05	0.000158	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1R—sarcoma	2.53e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PLCG1—sarcoma	2.52e-05	0.000156	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—sarcoma	2.52e-05	0.000156	CbGpPWpGaD
Sirolimus—MTOR—Disease—PDGFRA—sarcoma	2.51e-05	0.000156	CbGpPWpGaD
Sirolimus—FGF2—Disease—CREB1—sarcoma	2.5e-05	0.000155	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—sarcoma	2.48e-05	0.000154	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—JUN—sarcoma	2.48e-05	0.000154	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CTNNB1—sarcoma	2.46e-05	0.000152	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KIT—sarcoma	2.43e-05	0.00015	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCR4—sarcoma	2.42e-05	0.00015	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FOXO1—sarcoma	2.41e-05	0.000149	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PDGFRB—sarcoma	2.41e-05	0.000149	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ATF1—sarcoma	2.4e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—sarcoma	2.39e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—sarcoma	2.38e-05	0.000148	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PLCG1—sarcoma	2.38e-05	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PDGFRA—sarcoma	2.37e-05	0.000147	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CTNNB1—sarcoma	2.35e-05	0.000146	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—sarcoma	2.33e-05	0.000144	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.32e-05	0.000144	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CREB1—sarcoma	2.31e-05	0.000143	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—sarcoma	2.27e-05	0.00014	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—JUN—sarcoma	2.26e-05	0.00014	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.26e-05	0.00014	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CTNNB1—sarcoma	2.25e-05	0.000139	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MDM2—sarcoma	2.24e-05	0.000139	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—SRC—sarcoma	2.22e-05	0.000138	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—sarcoma	2.21e-05	0.000137	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—sarcoma	2.14e-05	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—SRC—sarcoma	2.14e-05	0.000132	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SRC—sarcoma	2.13e-05	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIT—sarcoma	2.11e-05	0.000131	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—sarcoma	2.11e-05	0.000131	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.08e-05	0.000129	CbGpPWpGaD
Sirolimus—FGF2—Disease—MDM2—sarcoma	2.07e-05	0.000128	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—sarcoma	2.06e-05	0.000127	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—sarcoma	2.05e-05	0.000127	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.03e-05	0.000126	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SRC—sarcoma	2.03e-05	0.000126	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO2—sarcoma	2.03e-05	0.000126	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—sarcoma	2.03e-05	0.000125	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HBA1—sarcoma	2.02e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CREB1—sarcoma	2.01e-05	0.000124	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—sarcoma	2e-05	0.000124	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KDR—sarcoma	2e-05	0.000124	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—sarcoma	1.98e-05	0.000122	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—sarcoma	1.95e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—sarcoma	1.95e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Disease—KIT—sarcoma	1.95e-05	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Immune System—JUN—sarcoma	1.95e-05	0.00012	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—sarcoma	1.93e-05	0.00012	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.92e-05	0.000119	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MDM2—sarcoma	1.91e-05	0.000118	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—sarcoma	1.91e-05	0.000118	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1R—sarcoma	1.88e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—sarcoma	1.87e-05	0.000116	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—sarcoma	1.86e-05	0.000115	CbGpPWpGaD
Sirolimus—MTOR—Disease—CREB1—sarcoma	1.85e-05	0.000115	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—sarcoma	1.84e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KIT—sarcoma	1.84e-05	0.000114	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—sarcoma	1.82e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FOXO1—sarcoma	1.79e-05	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PDGFRB—sarcoma	1.79e-05	0.000111	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—sarcoma	1.78e-05	0.00011	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—sarcoma	1.78e-05	0.00011	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—sarcoma	1.77e-05	0.000109	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—sarcoma	1.76e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PDGFRA—sarcoma	1.76e-05	0.000109	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CREB1—sarcoma	1.75e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Immune System—SRC—sarcoma	1.75e-05	0.000108	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PLCG1—sarcoma	1.72e-05	0.000107	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—sarcoma	1.71e-05	0.000106	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.71e-05	0.000106	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—sarcoma	1.68e-05	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—sarcoma	1.68e-05	0.000104	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—sarcoma	1.66e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MDM2—sarcoma	1.66e-05	0.000103	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—JUN—sarcoma	1.66e-05	0.000103	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—sarcoma	1.65e-05	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Disease—SRC—sarcoma	1.61e-05	9.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—sarcoma	1.57e-05	9.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—sarcoma	1.55e-05	9.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MDM2—sarcoma	1.53e-05	9.5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—sarcoma	1.53e-05	9.48e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—sarcoma	1.53e-05	9.47e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HBA1—sarcoma	1.52e-05	9.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—sarcoma	1.5e-05	9.31e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—sarcoma	1.5e-05	9.27e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—sarcoma	1.49e-05	9.25e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—sarcoma	1.49e-05	9.22e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—sarcoma	1.48e-05	9.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—sarcoma	1.48e-05	9.17e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—sarcoma	1.45e-05	8.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MDM2—sarcoma	1.45e-05	8.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—sarcoma	1.45e-05	8.95e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—sarcoma	1.44e-05	8.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—sarcoma	1.44e-05	8.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—sarcoma	1.43e-05	8.87e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—sarcoma	1.43e-05	8.87e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—sarcoma	1.43e-05	8.85e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—sarcoma	1.41e-05	8.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—sarcoma	1.36e-05	8.44e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—sarcoma	1.33e-05	8.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—sarcoma	1.33e-05	8.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—sarcoma	1.32e-05	8.19e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—sarcoma	1.31e-05	8.08e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PLCG1—sarcoma	1.3e-05	8.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CREB1—sarcoma	1.3e-05	8.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—sarcoma	1.3e-05	8.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—sarcoma	1.29e-05	8.01e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—sarcoma	1.26e-05	7.81e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—sarcoma	1.26e-05	7.79e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—sarcoma	1.25e-05	7.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—sarcoma	1.25e-05	7.72e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—sarcoma	1.23e-05	7.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—sarcoma	1.23e-05	7.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—sarcoma	1.2e-05	7.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—sarcoma	1.15e-05	7.12e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—sarcoma	1.14e-05	7.03e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—sarcoma	1.13e-05	7.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—sarcoma	1.13e-05	6.99e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—sarcoma	1.1e-05	6.81e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—sarcoma	1.1e-05	6.79e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—sarcoma	1.09e-05	6.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MDM2—sarcoma	1.07e-05	6.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—sarcoma	1.07e-05	6.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—sarcoma	1.07e-05	6.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—sarcoma	1.05e-05	6.49e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—sarcoma	1.05e-05	6.49e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—sarcoma	1.01e-05	6.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—sarcoma	9.9e-06	6.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—sarcoma	9.89e-06	6.12e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—sarcoma	9.6e-06	5.94e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—sarcoma	9.43e-06	5.84e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HBA1—sarcoma	9.37e-06	5.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—sarcoma	9.36e-06	5.79e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—sarcoma	9.35e-06	5.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—sarcoma	9.34e-06	5.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—sarcoma	9.27e-06	5.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—sarcoma	9.12e-06	5.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—sarcoma	8.42e-06	5.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—sarcoma	8.38e-06	5.19e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—sarcoma	8.31e-06	5.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—sarcoma	8.16e-06	5.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—sarcoma	8.06e-06	4.99e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLCG1—sarcoma	8e-06	4.95e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—sarcoma	7.94e-06	4.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—sarcoma	7.51e-06	4.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—sarcoma	7.34e-06	4.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—sarcoma	6.94e-06	4.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—sarcoma	6.16e-06	3.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—sarcoma	5.9e-06	3.65e-05	CbGpPWpGaD
